BioCatalystWatch
APLMWorkspace / APLM / OverviewCompany library
Apollomics Inc. logo

Apollomics Inc.

Apollomics Inc. (APLM)

Website

Featured programme · Vebreltinib (APL-101/PLB1001)

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Other pipelines

Partner / License out

PD-L1

Approved

PreINDP1P2P3FilingApproved

PD-L1

Approved

PreINDP1P2P3FilingApproved

PD-L1

Approved

PreINDP1P2P3FilingApproved

History / paused

VEGFR × VEGFR-2 × B-RAF × C-RAF × CSF1R

PreINDP1P2P3FilingApproved

E-selectin

EGFR (ErbB1) × HER2 (ErbB2) × HER4 (ErbB4)

PreINDP1P2P3FilingApproved

Gastrin (G17)

PreINDP1P2P3FilingApproved

E-selectin

PreINDP1P2P3FilingApproved

PD-1

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

APLM PR & News

APLM SEC archive